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Abstract
Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI
therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated
with long-term toxicities, graft loss and patient death. Therefore, alternative immunosuppressive strategies are needed
that combine excellent efficacy with low incidences of long-term adverse outcomes.
This review focuses on the strategies based on mTOR- inhibitors in combination with minimized exposure to CNI.
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Introduction
Modern immunosuppressive regimens after kidney trans-
plantation are associated with very low acute rejection
rates during the first year and excellent 1-year graft and
patient survival. Usually, 1-year acute rejection rates are
observed to be between 5 and 15 % in a therapy based on
calcineurin-inhibitors (CNI) and mycophenolate mofetil
or mycophenolate sodium (MMF/MPA) [1]. One-year
patient survival can be expected to be above 90 % as well
as 1-year graft survival. The above-mentioned immuno-
suppressive regimens based on a CNI and MMF, however,
are associated with considerable toxicities and other drug-
related adverse events such as direct nephrotoxicity, wors-
ening of several cardiovascular risk factors and a higher
incidence of cardiovascular events compared with the
general population, a higher incidence of post-transplant
cancer as well as a high incidence of viral infections such
as CMV, BKV and oncogenic viruses. Many of these ad-
verse events can be attributed to CNIs directly or the
combination of a CNI with MMF. Moreover, many of
these adverse effects are CNI-dose-dependent. During the
last 30 years the search for an alternative to the potent
CNIs has not yielded a treatment that is routinely
employed. Belatacept-based therapy might be an alterna-
tive in patients with low to moderate immunological risk
[2], however, it has not yet acquired an important market
share, partly due to its high cost and partly due to
concerns about less immunosuppressive potency. The
dilemma of current immunosuppressive therapy is as thus:
the need to use a drug for its potency in the absence of an
equivalent alternative but one which is associated with
toxicities that favor the development of complications or
risk factors that can ultimately lead to the death of the
patient such as hypertension, nephrotoxicity, viral infec-
tions, diabetes mellitus and cancer. In fact, the main
causes of death of kidney allograft recipients beyond 1 year
post-transplant are fatal cardiovascular events and post-
transplant malignancy [3]. This dilemma has led to the
development of immunosuppressive strategies that CNIs
and maintain a sufficient long-term immunosuppressive
potency. These regimens – based on just the necessary
exposure to CNIs with potent concomitant immunosup-
pressive medication – reflect the current international
guidelines recommending the combination of a CNI (pref-
erably tacrolimus [TAC]) and MMF [4]. This therapy has
led to the best results in terms of graft and patient survival
so far but these results are still not satisfactory, since the
main causes of death are still cardiovascular events and
cancer, and the main reasons for long-term graft loss are
antibody-mediated damage and chronic rejection [5]. In
other words, further minimizing CNI exposure in a CNI/
MMF combination will result in more immunological
damage long-term while incrementing the CNI exposure
will result in a higher incidence of CNI-associated
adverse events. Therefore, several strategies that allow
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potent immunosuppression and low toxicities have been
developed. This review will focus on strategies based on
mTOR-inhibitors, and especially based on sirolimus.
mTOR-inhibitor-based CNI avoidance de novo and early
conversion
mTOR-based CNI avoidance de novo
The quest for avoiding CNI exposure has led to several
studies of complete CNI avoidance de novo [1, 6]. How-
ever, only one monocenter study comparing an mTOR-
inhibitor-based conversion with induction with an IL2R-
antibody with a CNI-based regimen, yielded satisfactory
results in favor of the mTOR-inhibitor [7]. Other multi-
center studies with a comparable regimen showed higher
acute rejection rates in the mTOR-inhibitor-based arms
[1, 6]. An alternative would be to add induction with a
lymphocyte-depleting antibody to yield better efficacy.
Lebranchu et al. conducted a study comparing cyclospor-
ine A (CsA), MMF and a steroid regimen with sirolimus,
MMF and steroid regimen. Patients in both arms received
induction treatment with anti-thymocyte globulin. Effi-
cacy, graft and patient survival as well as renal function at
1 year were comparable in both arms [8]. However, in
general mTOR-inhibitor-based CNI-free de novo regi-
mens have been associated with a high incidence of
side effects and have therefore not found their way
into clinical routine treatment.
mTOR-inhibitor-based early conversion
Lebranchu et al. performed a study of early conversion
from CsA-based treatment to sirolimus at 3 months
post-transplantation in combination with MMF and oral
steroids, with planned discontinuation at month 8 [9]. A
total of 192 of 237 patients were converted. Cockcroft-
Gault-clearance at 1 year was significantly better in the
sirolimus group (68.9 vs. 64.4 mL/min). Patient and graft
survival were not statistically different. The incidence of
acute rejection episodes, mainly occurring after with-
drawal of steroids, was numerically, but not statistically
higher in the sirolimus group (17 % vs. 8 %, p = 0.071).
Sixteen patients discontinued sirolimus, mainly for ad-
verse events (n = 11), and seven patients discontinued
CsA for renal failure or acute rejection. Significantly
more patients in the sirolimus group reported aphthous
ulcers, diarrhea, acne and high triglyceride levels.
Budde et al. performed a similar trial of early conver-
sion from Cs A to everolimus 4.5 months after transplant-
ation [10]. Five hundred and three patients were
included, however only 60 % of these patients could
be randomized to receive everolimus, or continue stand-
ard CsA-based treatment. Patients in both arms re-
ceived MMF. Everolimus patients experienced a
significant improvement in glomerular filtration rate
(GFR) (71.8 mL/min vs 61.9 mL/min). However, rates of
biopsy-proven acute rejection were higher in the everoli-
mus group after conversion (10 % vs 3 %). Recently pub-
lished 5-year confirmed the 1 year results with an overall
higher rate of acute rejection, but significantly better kid-
ney allograft function [11].
Weir and colleagues evaluated early CNI withdrawal
and introduction of sirolimus in combination with MMF
[12]. After 1 year, the mean percentage change from base-
line in measured GFR was significantly higher in the
MMF/sirolimus group compared with the MMF/CNI
group, however, at 2 years, the change was indistin-
guishable. Calculated creatinine clearance and GFR
were significantly greater with MMF/sirolimus at 2 years.
Biopsy-proven acute rejection occurred in 14 MMF/siroli-
mus-treated patients (3 graft losses) and in 17 receiving
MMF/CNI (6 graft losses). No patients died receiving
MMF/sirolimus, but five treated with MMF/CNI did.
Conversion patients participating in the ZEUS trial
who were evaluated in a separate analysis showed a
higher incidence of de novo donor-specific antibodies
[13]. Most of these patients had also the steroids with-
drawn. The observed phenomenon by Liefeldt et al might
possibly reflect under-immunosuppression rather than a
genuine drug effect.
Moreover, in the above-mentioned conversion trials
more patients were withdrawn from the mTOR-
inhibitor-based treatment due to adverse events.
In general, early CNI withdrawal with subsequent
mTOR-inhibitor-based treatment is a valid strategy for a
select group of patients, however, it should not be offered
to patients with moderate-to-high immunological risk as
it is associated with a higher incidence of adverse events.
Practical considerations for conversion from a calcineurin
inhibitor to an mTOR- inhibitor
Planned or reactive conversion strategies have yielded a
variety of results depending on the drug combinations,
patient selection and timing of the conversion. Reactive
conversion from a CNI to an mTOR-inhibitor is safe in
terms of graft and patient survival and acute rejection
rates, however, it does not result in significant improve-
ment of graft function [14]. Early or very early conversion
may be associated with a higher rate of adverse events [15,
16]. All conversion studies share common drawbacks. A
certain number of patients cannot or do not want to be
converted for various reasons. A planned conversion
usually takes place in a situation when the patient is
asymptomatic, and psychologically, this might not be an
ideal moment to convince a patient of the necessity of a
new treatment with potential new side effects. Conse-
quently, a higher number of adverse events results in a
higher number of withdrawals in the conversion patients
[9, 10, 15].
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Therefore, for many patients it might be reasonable to
receive a de novo treatment that is also used later on as
the maintenance treatment.
In spite of this the following situations might give rise
to a reactive conversion to SRL:
 CNI-associated cosmetic side effects
 BKV or CMV infection
 Papilloma virus infections
 Skin cancer and solid organ other cancers
 CNI-associated neurotoxicity
Minimization of calcineurin inhibitors in combination with
mTOR- inhibitors
CNIs are the mainstay of immunosuppression after kidney
transplantation and rejection rates as low as 7 % during the
first year have been achieved [2]. No standard immunosup-
pressive regimen free of CNI has been associated with such
low rejection rates. In contrast, post-transplant malignancy
and CNI nephrotoxicity have both been associated in a
dose-dependent manner with CNI. mTOR-inhibitors offer
a superb opportunity to minimize CNI exposure and thus
reduce potential hazardous CNI-associated side effects.
The combination of mTOR-inhibitors and low-dose tacro-
limus is probably the most potent immunosuppressive
regimen after kidney transplantation in the era of modern
immunosuppression.
mTOR- inhibitors were first used in combination with
CsA in the second half of the 1990s and, at that time, re-
sulted in remarkably low acute rejection rates without in-
duction therapy. However, two major drawbacks were
associated with this therapeutic approach: CNI and mTOR-
inhibitors at full doses are associated with a number of se-
vere side effects and secondly mTOR-inhibitors increased
the nephrotoxicity of CsA. Consequently, different dosing
strategies were developed including a reduction in the
mTOR-inhibitor dose used, since most of the mTOR-
inhibitor-associated side effects are dose-dependent.
Furthermore, due to the immunosuppressive potency of the
combination, CNI exposure could be drastically lowered.
Clinical data on the use of mTOR-inhibitors in
combination with low-dose tacrolimus are limited.
Langer et al. showed that treatment with everolimus
allowed early and substantial tacrolimus minimization
when used with basiliximab induction and corticoste-
roids [17]. In this study 234 patients were randomized at
month four to receive very low-dose tacrolimus treat-
ment (2–4 ng/mL) or low-dose tacrolimus (4–7 ng/mL)
in combination with everolimus and steroids. During the
first 3 months, patients received low-dose tacrolimus in
combination with everolimus and steroid treatment as
well as basiliximab induction. At 1 year, acute rejection
rates were comparable between cohorts. In the study
arm a tacrolimus concentration of 3.4 ng/mL was
achieved. This study demonstrated the feasibility of ex-
tremely low tacrolimus doses in combination with an
mTOR-inhibitor.
Sirolimus has also been used successfully in combin-
ation with low-dose tacrolimus, resulting in comparable
efficacy and less nephrotoxicity when compared with
sirolimus in combination with standard dose tacrolimus.
Russ and colleagues studied 64 patients who received
sirolimus in combination with reduced dose or stand-
ard dose tacrolimus. Patient and graft survival as well
as the incidence of acute rejection were no different
between the groups with different tacrolimus exposure.
Moreover, reduced tacrolimus exposure combined with
sirolimus showed a trend towards better renal function
while simultaneously maintaining comparable acute
rejection rates [18].
Peddi et al. reviewed CNI minimization therapy
in combination with an mTOR-inhibitor [19]. They
Table 1 Overview of studies with sirolimus
Author Study arm Control arm Outcome
Ekberg et al. [1] Dac + SRL low +MMF + S (a) CsA +MMF + S (d) Higher AR in SRL arm (a. 37 %, b 24 %, c 12 %,
d 26 %)
Dac + CsA low +MMF + S (b)
Dac + Tac low +MMF + S (c)
Flechner et al. [6] Dac + SRL + MMF + S (e) Dac + Tac +MMF + S (g) Higher AR in SRL/MMF (e 31 %, f 15 %, g 8 %)
Dac + SRL + Tac WD + S (f)
Flechner et al. [7] Dac + SRL + MMF + S Dac + CsA + MMF + S Better GFR in SRL arm (67 vs. 51 mL/min)
Lebranchu et al. [8] Thy + SRL +MMF + S Thy + CsA +MMF + S Better GFR in SRL arm (54 vs. 45 mL/min)
Lebranchu et al. [9] Dac + CsA +MMF + S early conversion to SRL Dac + CsA + MMF + S Better GFR in SRL arm (69 vs. 64 mL/min)
c [12] CNI + MMF+/−S (+/− induction) early
conversion to SRL
CNI + MMF+/−S (+/− induction) No difference in GFR change at 2 yrs
Guba et al. [15] ATG + CsA +MMF + S very early conversion ATG + CsA +MMF + S Better GFR in SRL arm (65 vs. 53 mL/min)
Dac Daclizumab, SRL Sirolimus, MMF Mycophenolate mofetil, S steroids, CsA Cyclosporine A, Tac Tacrolimus, AR acute rejection rate, WD withdrawal,
GFR glomerular filtration rate, Thy Thymoglobuline®, CNI Calcineurin inhibitor, ATG ATG Fresenius®
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identified and evaluated 21 relevant studies and
concluded that immunosuppressive regimens including
an mTOR-inhibitor and tacrolimus minimization better
preserve renal function versus standard-dose tacroli-
mus, without significant changes in patient survival or
graft rejection rates. Rates of infection and malignancies
were low. Other adverse events were more commonly
reported including dyslipidemia/hyperlipidemia in up to
two thirds of patients, new-onset diabetes mellitus in up
to 38 %, wound complications in up to 22 %, and hyper-
tension in up to 17 %.
Sirolimus dosing in combination with tacrolimus
Kahan et al. found that renal transplant recipients
treated with sirolimus and CsA achieved sufficient
protection from acute rejection with sirolimus concentra-
tions > 5 ng/mL [20], whereas an acceptable rate of
adverse events was achieved with concentrations < 15 ng/
mL. So far, a similar assessment for the combination of
sirolimus and tacrolimus has not been performed.
However, data from the ASSET trial [17] showed that
mTOR-inhibitor concentrations of > 3 ng/mL in combin-
ation with a CNI offer sufficient protection from rejection.
Adverse effects of mTOR-inhibitors appear to be
dose-related [20]. Therefore, sirolimus drug levels need
to be carefully monitored. Monitoring of sirolimus trough
concentrations and careful evaluation of possible adverse
reactions is the key to avoiding side effects and improving
side effect management. Loading doses of sirolimus
should be avoided.
Sirolimus dose requirements vary with the type of CNI
used. Ciancio and colleagues demonstrated that siroli-
mus exposure is lower in combination with TAC than
with CsA [21]. Therefore, higher sirolimus doses are
needed in combination with tacrolimus compared
with the sirolimus/ CsA combination.
Conclusions
mTOR-inhibitors can be used as non-nephrotoxic drugs
in order to minimize CNI exposure. This drug combin-
ation has enabled dramatic CNI dose reductions in the
early post-transplant phase. Both CNI and mTOR-
inhibitors have a narrow therapeutic window and a high
risk of side effects. Moreover, they are characterized by
high intraindividual and interindividual differences of
dosing requirements. Therefore, therapeutic drug moni-
toring of both drugs are necessary. A summary of the
different studies of use of the mTOR-inhibitors with
and without CNIs either de novo or in early conversion
is given in Tables 1 and 2. Possible indications and dis-
advantages are summarized in Table 3.
Table 2 Overview of studies with everolimus
Author Study arm Control arm Outcome
Budde et al. [10, 11] Bas + CsA +MPS + S early conversion
to EVR
Bas + CsA +MPS + S Better GFR EVR arm at 1 yr and at 5 yrs (72 vs. 62 mL/min
at 1 yr); overall higher rate of AR
Mjörnstedt et al. [16] CsA +MPS + S early conversion to EVR
(7 weeks)
CsA +MPS + S GFR change 4.9 vs 0 mL/min (EVR vs CsA)
Langer et al. [17] Bas + Tac low + EVR + S + conversion
Tac very low
Bas + Tac low + EVR + S No difference in AR post-conversion; GFR 57 vs. 51 mL/min
(p = 0.0299)
S steroids, CsA Cyclosporine A, Tac Tacrolimus, AR acute rejection rate, WD withdrawal, GFR glomerular filtration rate, Bas Basiliximab, MPS Mycophenolate Sodium,
EVR Everolimus
Table 3 Possible indications and disadvantages
Treatment regimen Patients who might benefit Disadvantages
De novo mTOR-I-based without CNI - Low immunological risk patients - Wound-healing problems in obese patients
- CNI-related side effects to be anticipated (neurotoxicity,
nephrotoxicity, CNI-associated hemolytic uremic syndrome)
- High incidence of side effects of mTOR-I and
mycophenolate combination
- Patients at risk of CMV or BKV infection - Probably induction with lymphocyte-depleting
antibodies necessary
- Patients at risk of post-transplant malignancy
De novo mTOR-I and CNI combination - Low and intermediate immunological risk patients - Wound-healing problems in obese patients
- Patients who do not tolerate an adequate dose of
mycophenolate
- Possible risk of new-onset diabetes
- Patients at risk of CMV or BKV infection
- Patients at risk of post-transplant malignancy
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